You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


AlzeCure begins Alzheimer’s therapy development phase

AlzeCure – a company that develops a portfolio of small molecule drug candidates for diseases affecting the central nervous system – has announced that it has selected a candidate drug and started the preclinical development phase with its Alzheimer’s candidate ACD680.